MPN Research Updates from ASH 2022

ASH 2022

Each year, the American Society of Hematology (ASH) Annual Meeting and Exposition convenes over 25,000 clinicians and scientists from around the world to discuss the latest research and treatments for blood cancers and other blood disorders.

This year, at the 64th Annual ASH Meeting in New Orleans, the Weill Cornell Medicine (WCM) Silver Myeloproliferative Neoplasm (MPN) Center team was involved with several research studies. We are proud to highlight some of the work our physicians and scientists were part of at ASH 2022.

Dr. Joseph Scandura, Scientific Director of the Silver MPN Center presented initial results from a phase two clinical trial evaluating the use of the BET inhibitor pelabresib alone or in combination with ruxolitinib for myelofibrosis. Scandura Quote

Dr. Nicole Kucine shared details on findings from the HEMEPACT study, which looked at identifying genetic mutations in children with myeloproliferative neoplasms (MPNs). This was one of the largest analyses to-date of gene mutations in pediatric MPN patients. While pediatric MPNs are rare, this research aims to improve upon the way these patients’ diseases are currently managed and treated. Kucine Quote

Dr. Ghaith Abu-Zeinah shares research findings from a study led by the Silver MPN Center looking at mutant allele frequency (MAF) in polycythemia vera patients with the JAK2V617F mutation.

Abu-Zeinah Quote

Weill Cornell Medicine Hematology & Oncology Fellow Dr. Franco Castillo Tokumori broke down a meta-analysis looking at a type of JAK2 mutation in polycythemia vera. This research took place at the Silver MPN Center under the mentorship of team members Drs. Scandura and Abu-Zeinah.

Franco Quote

The Silver MPN Center team collaborated with medical students at Weill Cornell Medicine-Qatar for a research project evaluating cytoreductive agents for younger patients with polycythemia vera. Medical student Reem Chamseddine commented on this project.

reem quote

Dr. Daniel Choi, a physician-scientist at Weill Cornell Medicine who is focused on myeloproliferative neoplasm research, discusses research conducted at the Silver MPN Center examining a cohort of polycythemia vera patients. Dr. Choi and Silver MPN Center team members looked at the additional implications the JAK2 mutation has on polycythemia vera patients.

choi quote

Dr. Joseph Scandura was involved with a phase I/II clinical trial evaluating an investigational therapy aimed at targeting PIM1 genes for patients with myelofibrosis. Read more about this study. 
scandura quote

The Weill Cornell Medicine Silver MPN Center is proud to have been selected to contribute our research and expertise at this year’s ASH meeting in order to provide updates on the latest therapies and research that are being developed for myeloproliferative neoplasms. We continue to study these diseases and lead MPN research throughout the year in an effort to enhance the lives of patients and their loved ones impacted by MPNs.

Richard T. Silver MD Myeloproliferative Neoplasms Center 525 East 70th St., Starr Pavillion, 3rd Floor New York, NY 10021